Skip to main content
Erschienen in: Inflammation 1/2018

06.09.2017 | ORIGINAL ARTICLE

Cepharanthine Inhibits IFN-γ-Induced CXCL10 by Suppressing the JAK2/STAT1 Signal Pathway in Human Salivary Gland Ductal Cells

verfasst von: Keiko Aota, Tomoko Yamanoi, Koichi Kani, Masayuki Azuma

Erschienen in: Inflammation | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Cepharanthine, a biscolaurine alkaloid isolated from the plant Stephania cephalantha Hayata, has been reported to have potent anti-inflammatory properties. Here, we investigated the effects of cepharanthine on the expression of CXCL10 (a CXC chemokine induced by interferon-gamma [IFN-γ] that has been observed in a wide variety of chronic inflammatory disorders and autoimmune conditions) in IFN-γ-treated human salivary gland cell lines. We observed that IFN-γ-induced CXCL10 production in NS-SV-DC cells (a human salivary gland ductal cell line), but not in NS-SV-AC cells (a human salivary gland acinar cell line). Cepharanthine inhibited the IFN-γ-induced CXCL10 production in NS-SV-DC cells. A Western blot analysis showed that cepharanthine prevented the phosphorylation of JAK2 and STAT1, but did not interfere with the NF-κB pathway. Moreover, cepharanthine inhibited the IFN-γ-mediated chemotaxis of Jurkat T cells. These results suggest that cepharanthine suppresses IFN-γ-induced CXCL10 production via the inhibition of the JAK2/STAT1 signaling pathway in human salivary gland ductal cells. Our findings also indicate that cepharanthine could inhibit the chemotaxis of Jurkat T cells by reducing CXCL10 production.
Literatur
1.
Zurück zum Zitat Alspaugh, M.A., and K. Whaley. 1981. In Sjögren’s syndrome, textbook of Rheumatology, ed. W.N. Kelley, E.D. Harris, S. Ruddy, and C.B. Sledge, 971–999. Philadelphia: W.B. Saunders. Alspaugh, M.A., and K. Whaley. 1981. In Sjögren’s syndrome, textbook of Rheumatology, ed. W.N. Kelley, E.D. Harris, S. Ruddy, and C.B. Sledge, 971–999. Philadelphia: W.B. Saunders.
2.
Zurück zum Zitat Daniels, T.E. 1984. Labial salivary gland biopsy in Sjögren's syndrome: Assessment as a diagnostic criterion in 362 suspected cases. Arthritis and Rheumatism 27: 147–156.CrossRefPubMed Daniels, T.E. 1984. Labial salivary gland biopsy in Sjögren's syndrome: Assessment as a diagnostic criterion in 362 suspected cases. Arthritis and Rheumatism 27: 147–156.CrossRefPubMed
3.
Zurück zum Zitat Hamano, H., I. Saito, N. Haneji, Y. Mitsuhashi, and Hayashi Y. MiyasakaN. 1993. Expressions of cytokine genes during development of autoimmune sialadenitis in MRL/lpr mice. European Journal of Immunology 23: 2387–2391.CrossRefPubMed Hamano, H., I. Saito, N. Haneji, Y. Mitsuhashi, and Hayashi Y. MiyasakaN. 1993. Expressions of cytokine genes during development of autoimmune sialadenitis in MRL/lpr mice. European Journal of Immunology 23: 2387–2391.CrossRefPubMed
4.
Zurück zum Zitat Fox, R.I., H.I. Kang, D. Ando, J. Abrams, and E. Pisa. 1994. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. Journal of Immunology 152: 5532–5529. Fox, R.I., H.I. Kang, D. Ando, J. Abrams, and E. Pisa. 1994. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. Journal of Immunology 152: 5532–5529.
6.
Zurück zum Zitat Hall, J.C., A.N. Baer, A.A. Shah, L.A. Criswell, C.H. Shiboski, A. Rosen, and L. Casciola-Rosen. 2015. Molecular subsetting of interferon pathways in Sjögren's syndrome. Arthritis & Rhematology 67: 2437–2446.CrossRef Hall, J.C., A.N. Baer, A.A. Shah, L.A. Criswell, C.H. Shiboski, A. Rosen, and L. Casciola-Rosen. 2015. Molecular subsetting of interferon pathways in Sjögren's syndrome. Arthritis & Rhematology 67: 2437–2446.CrossRef
7.
Zurück zum Zitat Nocturne, G., and X. Mariette. 2013. Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nature Reviews. Rheumatology 9: 544–556.CrossRefPubMed Nocturne, G., and X. Mariette. 2013. Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nature Reviews. Rheumatology 9: 544–556.CrossRefPubMed
8.
Zurück zum Zitat Luster, A.D., J.C. Unkeless, and J.V. Ravetch. 1985. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315: 672–676.CrossRefPubMed Luster, A.D., J.C. Unkeless, and J.V. Ravetch. 1985. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315: 672–676.CrossRefPubMed
9.
Zurück zum Zitat García-López, M.A., F. Sánchez-Madrid, J.M. Rodríguez-Frade, M. Mellado, A. Acevedo, M.I. García, J.P. Albar, C. Martínez, and M. Marazuela. 2001. CXCR3 chemokine receptor distribution in normal and inflamed tissues: Expression on activated lymphocytes, endothelial cells, and dendritic cells. Laboratory Investigation 81: 409–418.CrossRefPubMed García-López, M.A., F. Sánchez-Madrid, J.M. Rodríguez-Frade, M. Mellado, A. Acevedo, M.I. García, J.P. Albar, C. Martínez, and M. Marazuela. 2001. CXCR3 chemokine receptor distribution in normal and inflamed tissues: Expression on activated lymphocytes, endothelial cells, and dendritic cells. Laboratory Investigation 81: 409–418.CrossRefPubMed
10.
Zurück zum Zitat Groom, J.R., and A.D. Luster. 2011. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunology and Cell Biology 89: 207–215.CrossRefPubMed Groom, J.R., and A.D. Luster. 2011. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunology and Cell Biology 89: 207–215.CrossRefPubMed
11.
Zurück zum Zitat Hartl, D., S. Krauss-Etschmann, B. Koller, P.L. Hordijk, T.W. Kuijpers, F. Hoffmann, A. Hector, E. Eber, V. Marcos, I. Bittmann, O. Eickelberg, M. Griese, and D. Roos. 2008. Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases. Journal of Immunology 181: 8053–8067.CrossRef Hartl, D., S. Krauss-Etschmann, B. Koller, P.L. Hordijk, T.W. Kuijpers, F. Hoffmann, A. Hector, E. Eber, V. Marcos, I. Bittmann, O. Eickelberg, M. Griese, and D. Roos. 2008. Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases. Journal of Immunology 181: 8053–8067.CrossRef
12.
Zurück zum Zitat Tomita, K., B.L. Freeman, S.F. Bronk, N.K. LeBrasseur, T.A. White, P. Hirsova, and S.H. Ibrahim. 2016. CXCL10-mediates macrophage, but not other innate immune cells-associated inflammation in murine nonalcoholic steatohepatitis. Scientific Reports 6: 28786.CrossRefPubMedPubMedCentral Tomita, K., B.L. Freeman, S.F. Bronk, N.K. LeBrasseur, T.A. White, P. Hirsova, and S.H. Ibrahim. 2016. CXCL10-mediates macrophage, but not other innate immune cells-associated inflammation in murine nonalcoholic steatohepatitis. Scientific Reports 6: 28786.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Ogawa, N., L. Ping, L. Zhenjun, Y. Takada, and S. Sugai. 2002. Involvement of the interferon-γ-induced T cell-attracting chemokines, interferon-γ-inducible 10-kD protein (CXCL10) and monokine induced by interferon-γ (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome. Arthritis and Rheumatism 46: 2730–2741.CrossRefPubMed Ogawa, N., L. Ping, L. Zhenjun, Y. Takada, and S. Sugai. 2002. Involvement of the interferon-γ-induced T cell-attracting chemokines, interferon-γ-inducible 10-kD protein (CXCL10) and monokine induced by interferon-γ (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome. Arthritis and Rheumatism 46: 2730–2741.CrossRefPubMed
14.
Zurück zum Zitat Ogawa, N., T. Kawanami, K. Shimoyama, L. Ping, and S. Sugai. 2004. Expression of interferon-inducible T cell alpha chemoattractant (CXCL11) in the salivary glands of patients with Sjögren’s syndrome. Clinical Immunology 112: 235–238.CrossRefPubMed Ogawa, N., T. Kawanami, K. Shimoyama, L. Ping, and S. Sugai. 2004. Expression of interferon-inducible T cell alpha chemoattractant (CXCL11) in the salivary glands of patients with Sjögren’s syndrome. Clinical Immunology 112: 235–238.CrossRefPubMed
15.
Zurück zum Zitat Hasegawa, H., A. Inoue, M. Kohno, M. Muraoka, T. Miyazaki, M. Terada, T. Nakayama, O. Yoshie, M. Nose, and M. Yasukawa. 2006. Antagonist of interferon-inducible protein 10/CXCL10 ameliorates the progression of autoimmune sialadenitis in MRL/lpr mice. Arthritis and Rheumatism 54: 1174–1183.CrossRefPubMed Hasegawa, H., A. Inoue, M. Kohno, M. Muraoka, T. Miyazaki, M. Terada, T. Nakayama, O. Yoshie, M. Nose, and M. Yasukawa. 2006. Antagonist of interferon-inducible protein 10/CXCL10 ameliorates the progression of autoimmune sialadenitis in MRL/lpr mice. Arthritis and Rheumatism 54: 1174–1183.CrossRefPubMed
16.
Zurück zum Zitat Gutterman, J.U., S. Fine, J. Quesada, S.J. Horning, J.F. Levine, R. Alexanian, L. Bernhardt, M. Kramer, H. Spiegel, W. Colburn, P. Trown, T. Merigan, and Z. Dziewanowski. 1982. Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Annals of Internal Medicine 96: 549–556.CrossRefPubMed Gutterman, J.U., S. Fine, J. Quesada, S.J. Horning, J.F. Levine, R. Alexanian, L. Bernhardt, M. Kramer, H. Spiegel, W. Colburn, P. Trown, T. Merigan, and Z. Dziewanowski. 1982. Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Annals of Internal Medicine 96: 549–556.CrossRefPubMed
17.
Zurück zum Zitat Ono, M. 1987. Antitumor effect of cepharanthine: activation of regional lymph node lymphocytes by intratumoral administration. Clinical Immunology 19: 1061–1064. Ono, M. 1987. Antitumor effect of cepharanthine: activation of regional lymph node lymphocytes by intratumoral administration. Clinical Immunology 19: 1061–1064.
18.
Zurück zum Zitat Morioka, S., M. Ono, N. Tanaka, and K. Orita. 1985. Synergistic activation of rat alveolar macrophages by cepharanthine and OK-432. Gan to Kagaku Ryoho 12: 1470–1475.PubMed Morioka, S., M. Ono, N. Tanaka, and K. Orita. 1985. Synergistic activation of rat alveolar macrophages by cepharanthine and OK-432. Gan to Kagaku Ryoho 12: 1470–1475.PubMed
19.
Zurück zum Zitat Azuma, M., K. Aota, T. Tamatani, K. Motegi, T. Yamashita, Y. Ashida, Y. Hayashi, and M. Sato. 2002. Suppression of tumor necrosis factor α-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor κB: A possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjögren's syndrome patients. Arthritis and Rheumatism 46: 1585–1594.CrossRefPubMed Azuma, M., K. Aota, T. Tamatani, K. Motegi, T. Yamashita, Y. Ashida, Y. Hayashi, and M. Sato. 2002. Suppression of tumor necrosis factor α-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor κB: A possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjögren's syndrome patients. Arthritis and Rheumatism 46: 1585–1594.CrossRefPubMed
20.
Zurück zum Zitat Azuma, M., Y. Ashida, T. Tamatani, K. Motegi, N. Takamaru, N. Ishimaru, Y. Hayashi, and M. Sato. 2006. Cepharanthin, a biscoclaurine alkaloid, prevents destruction of acinar tissues in murine Sjögren’s syndrome. The Journal of Rheumatology 33: 912–920.PubMed Azuma, M., Y. Ashida, T. Tamatani, K. Motegi, N. Takamaru, N. Ishimaru, Y. Hayashi, and M. Sato. 2006. Cepharanthin, a biscoclaurine alkaloid, prevents destruction of acinar tissues in murine Sjögren’s syndrome. The Journal of Rheumatology 33: 912–920.PubMed
21.
Zurück zum Zitat Yamanoi, T., K. Aota, Y. Momota, and M. Azuma. 2017. Treatment with the biscoclaurine alkaloid cepharanthin for improved salivary secretion in primary Sjögren's syndrome patients. Journal of Oral Health Biosciences 29: 39–48. Yamanoi, T., K. Aota, Y. Momota, and M. Azuma. 2017. Treatment with the biscoclaurine alkaloid cepharanthin for improved salivary secretion in primary Sjögren's syndrome patients. Journal of Oral Health Biosciences 29: 39–48.
22.
Zurück zum Zitat Azuma, M., T. Tamatani, Y. Kasai, and M. Sato. 1993. Immortalization of normal human salivary gland cells with duct-, myoepithelial-, acinar-, or squamous phenotype by transfection of SV40 ori-mutant DNA. Laboratory Investigation 69: 24–42.PubMed Azuma, M., T. Tamatani, Y. Kasai, and M. Sato. 1993. Immortalization of normal human salivary gland cells with duct-, myoepithelial-, acinar-, or squamous phenotype by transfection of SV40 ori-mutant DNA. Laboratory Investigation 69: 24–42.PubMed
23.
Zurück zum Zitat Hogan, J.C., and J.M. Stephens. 2001. The identification and characterization of a STAT 1 binding site in the PPARγ2 promoter. Biochemical and Biophysical Research Communications 287: 484–492.CrossRefPubMed Hogan, J.C., and J.M. Stephens. 2001. The identification and characterization of a STAT 1 binding site in the PPARγ2 promoter. Biochemical and Biophysical Research Communications 287: 484–492.CrossRefPubMed
24.
Zurück zum Zitat Majumder, S., L.Z. Zhou, P. Chaturvedi, G. Babcock, S. Aras, and R.M. Ransohoff. 1998. p48/STAT-1alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha. Journal of Immunology 161: 4736–4744. Majumder, S., L.Z. Zhou, P. Chaturvedi, G. Babcock, S. Aras, and R.M. Ransohoff. 1998. p48/STAT-1alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha. Journal of Immunology 161: 4736–4744.
25.
Zurück zum Zitat Azuma, M., K. Motegi, K. Aota, Y. Hayashi, and M. Sato. 1997. Role of cytokines in the destruction of acinar structure in Sjögren’s syndrome salivary glands. Laboratory Investigation 77: 269–280.PubMed Azuma, M., K. Motegi, K. Aota, Y. Hayashi, and M. Sato. 1997. Role of cytokines in the destruction of acinar structure in Sjögren’s syndrome salivary glands. Laboratory Investigation 77: 269–280.PubMed
26.
Zurück zum Zitat Hall, J.C., L. Casciola-Rosen, A.E. Berger, E.K. Kapsogeorgou, C. Cheadle, A.G. Tzioufas, A.N. Baer, and A. Rosen. 2012. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proceedings of the National Academy of Sciences of the United States of America 109: 17609–17614.CrossRefPubMedPubMedCentral Hall, J.C., L. Casciola-Rosen, A.E. Berger, E.K. Kapsogeorgou, C. Cheadle, A.G. Tzioufas, A.N. Baer, and A. Rosen. 2012. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proceedings of the National Academy of Sciences of the United States of America 109: 17609–17614.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Lacotte, S., S. Brun, S. Muller, and H. Dumortier. 2009. CXCR3, inflammation, and autoimmune diseases. Annals of the New York Academy of Sciences 1173: 310–317.CrossRefPubMed Lacotte, S., S. Brun, S. Muller, and H. Dumortier. 2009. CXCR3, inflammation, and autoimmune diseases. Annals of the New York Academy of Sciences 1173: 310–317.CrossRefPubMed
28.
Zurück zum Zitat Gangur, V., F.E. Simons, and K.T. Hayglass. 1998. Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses. The FASEB Journal 12: 705–713.PubMed Gangur, V., F.E. Simons, and K.T. Hayglass. 1998. Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses. The FASEB Journal 12: 705–713.PubMed
29.
Zurück zum Zitat Qi, X.F., D.H. Kim, Y.S. Yoon, D. Jin, X.Z. Huang, J.H. Li, Y.K. Deung, and K.J. Lee. 2009. Essential involvement of cross-talk between IFN-γ and TNF-α in CXCL10 production in human THP-1 monocytes. Journal of Cellular Physiology 220: 690–697.CrossRefPubMed Qi, X.F., D.H. Kim, Y.S. Yoon, D. Jin, X.Z. Huang, J.H. Li, Y.K. Deung, and K.J. Lee. 2009. Essential involvement of cross-talk between IFN-γ and TNF-α in CXCL10 production in human THP-1 monocytes. Journal of Cellular Physiology 220: 690–697.CrossRefPubMed
30.
Zurück zum Zitat Kelner, G.S., J. Kennedy, K.B. Bacon, S. Kleyensteuber, D.A. Largaespada, N.A. Jenkins, N.G. Copeland, J.F. Bazan, K.W. Moore, T.J. Schall, et al. 1994. Lymphotactin: A cytokine that represents a new class of chemokine. Science 266: 1395–1399.CrossRefPubMed Kelner, G.S., J. Kennedy, K.B. Bacon, S. Kleyensteuber, D.A. Largaespada, N.A. Jenkins, N.G. Copeland, J.F. Bazan, K.W. Moore, T.J. Schall, et al. 1994. Lymphotactin: A cytokine that represents a new class of chemokine. Science 266: 1395–1399.CrossRefPubMed
31.
Zurück zum Zitat Murdoch, C., and A. Finn. 2000. Chemokine receptors and their role in inflammation and infectious diseases. Blood 95: 3032–3043.PubMed Murdoch, C., and A. Finn. 2000. Chemokine receptors and their role in inflammation and infectious diseases. Blood 95: 3032–3043.PubMed
Metadaten
Titel
Cepharanthine Inhibits IFN-γ-Induced CXCL10 by Suppressing the JAK2/STAT1 Signal Pathway in Human Salivary Gland Ductal Cells
verfasst von
Keiko Aota
Tomoko Yamanoi
Koichi Kani
Masayuki Azuma
Publikationsdatum
06.09.2017
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 1/2018
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-017-0662-x

Weitere Artikel der Ausgabe 1/2018

Inflammation 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.